Differential nicotinic receptor expression in monkey basal ganglia: effects of nigrostriatal damage.
Our previous work showed that there were marked declines in (125)I-alpha-conotoxin MII labeled nicotinic receptors in monkey basal ganglia after nigrostriatal damage, findings that suggest alpha3/alpha6 containing nicotinic receptors sites may be of relevance to Parkinson's disease. We now investigate whether there are differential changes in the distribution pattern of nicotinic receptor subtypes in the basal ganglia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned animals compared to controls to better understand the changes occurring with nigrostriatal damage. To approach this we used (125)I-alpha-conotoxin MII, a marker for alpha3/alpha6 nicotinic receptors, and (125)I-epibatidine, a ligand that labels multiple nicotinic subtypes. The results demonstrate that there were medial to lateral gradients in nicotinic receptor distribution in control striatum, as well as ventromedial to dorsolateral gradients in the substantia nigra, which resembled those of the dopamine transporter in these same brain regions. Treatment with MPTP, a neurotoxin that selectively destroys dopaminergic nigrostriatal neurons, led to a relatively uniform decrease in nicotinic receptor sites in the striatum, but a differential effect in the substantia nigra with significantly greater declines in the ventrolateral portion. Competition analysis in the striatum showed that alpha-conotoxin MII sensitive sites were primarily affected after lesioning, whereas multiple nicotinic receptor populations were decreased in the substantia nigra. From these data we suggest that in the striatum alpha3/alpha6 nicotinic receptors are primarily localized on dopaminergic nerve terminals, while multiple nicotinic receptor subtypes are present on dopaminergic cell bodies in the substantia nigra. Thus, if activation of striatal nicotinic receptors is key in the regulation of basal ganglia function, alpha3/alpha6-directed nicotinic receptor ligands may be more relevant for Parkinson's disease therapy. However, nicotinic receptor ligands with a broader specificity may be more important if receptors in the substantia nigra play a dominant role in controlling nigrostriatal activity.
Quik
M
M
The Parkinson's Institute, Sunnyvale, CA 94089, USA. mquik@parkinsonsinstitute.org
Polonskaya
Y
Y
McIntosh
J M
JM
Kulak
J M
JM
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D001392:Azocines; D001479:Basal Ganglia / Q000378:metabolism*; D001927:Brain Diseases / Q000139:chemically induced / Q000378:metabolism*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000037:antagonists & inhibitors / Q000378:metabolism; D002421:Caudate Nucleus / Q000378:metabolism; D020916:Conotoxins / Q000494:pharmacology; D003342:Corpus Striatum; D015259:Dopamine Agents; D005260:Female; D008297:Male; D018722:Nicotinic Agonists / Q000378:metabolism; D018733:Nicotinic Antagonists / Q000494:pharmacology; D011699:Putamen / Q000378:metabolism; D011725:Pyridines / Q000037:antagonists & inhibitors / Q000378:metabolism; D011807:Quinolizines; D011978:Receptors, Nicotinic / Q000378:metabolism*; D012016:Reference Values; D012453:Saimiri; D013378:Substantia Nigra; D014018:Tissue Distribution; D000093843:Quinolizidine Alkaloids
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000470:Alkaloids; D001392:Azocines; D019086:Bridged Bicyclo Compounds, Heterocyclic; D020916:Conotoxins; D015259:Dopamine Agents; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D011725:Pyridines; D011807:Quinolizines; D011978:Receptors, Nicotinic; C098872:alpha-conotoxin MII; C004712:cytisine; D000093843:Quinolizidine Alkaloids; C082748:epibatidine